Amlot, P L <br/><br/>
A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.  [electronic resource] 

 -  Blood  Nov 1993 
 - 2624-33 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0006-4971 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Animals<br/>Antibodies, Anti-Idiotypic--blood<br/>Antibodies, Monoclonal--therapeutic use<br/>Antigens, CD--immunology<br/>Antigens, Differentiation, B-Lymphocyte--immunology<br/>Blood Cells--drug effects<br/>Cell Adhesion Molecules<br/>Female<br/>Humans<br/>Immunotoxins--adverse effects<br/>Lectins<br/>Lymphoma, B-Cell--therapy<br/>Male<br/>Mice<br/>Middle Aged<br/>Ricin--immunology<br/>Sialic Acid Binding Ig-like Lectin 2<br/>Vascular Diseases--etiology